RESUMO
AIMS/OBJECTIVE: Conflicting data regarding cardiovascular effects of thiazolidinediones (TZDs) and extra-skeletal effects of vitamin D supported the need for a definitive trial. The Thiazolidinedione Intervention with vitamin D Evaluation (TIDE) trial aimed to assess the effects of TZDs (rosiglitazone and pioglitazone) on cardiovascular outcomes and the effects of vitamin D (cholecalciferol) on cancers and mortality. METHODS: A large multicentre 3 × 2 factorial double-blind placebo-controlled randomised trial recruited from outpatient primary care and specialty clinics in 33 countries. From June 2009 to July 2010, 1,332 people with type 2 diabetes and other cardiovascular risk factors aged ≥ 50 years whose HbA(1c) was 6.5-9.5% (48-80 mmol/mol) when using two or fewer glucose-lowering drugs were randomised by a central computer system to placebo (n = 541), rosiglitazone 4-8 mg/day (n = 399) or pioglitazone 30-45 mg/day (n = 392); 1,221 participants were randomised to placebo (n = 614) or vitamin D 1,000 IU/day (n = 607). Participants and all study personnel were blind to treatment allocation. The primary outcome for the TZD arm was the composite of myocardial infarction, stroke or cardiovascular death, and for the vitamin D arm it was cancer or all-cause death. All randomised participants were included in the primary analysis. RESULTS: From the study design, 16,000 people were to be followed for approximately 5.5 years. However, the trial was stopped prematurely because of regulatory concerns after a mean of 162 days without consideration of the accrued data. In the TZD arm, the cardiovascular outcome occurred in five participants (0.9%) in the placebo groups and three participants (0.4%) in the TZD groups (two allocated to pioglitazone, one to rosiglitazone). In the vitamin D arm, the primary outcome occurred in three participants (0.5%) in the placebo group and in two participants (0.3%) receiving vitamin D. Adverse events were comparable in all groups. CONCLUSIONS/INTERPRETATION: Uncertainty persists regarding the clinically relevant risks and benefits of TZDs and vitamin D because of the early cancellation of this comprehensive trial.
Assuntos
Colecalciferol/uso terapêutico , Diabetes Mellitus Tipo 2/dietoterapia , Diabetes Mellitus Tipo 2/tratamento farmacológico , Suplementos Nutricionais , Hipoglicemiantes/uso terapêutico , Tiazolidinedionas/uso terapêutico , Idoso , Doenças Cardiovasculares/complicações , Doenças Cardiovasculares/epidemiologia , Doenças Cardiovasculares/prevenção & controle , Colecalciferol/efeitos adversos , Terapia Combinada , Diabetes Mellitus Tipo 2/complicações , Relação Dose-Resposta a Droga , Método Duplo-Cego , Término Precoce de Ensaios Clínicos , Feminino , Humanos , Hipoglicemiantes/administração & dosagem , Hipoglicemiantes/efeitos adversos , Incidência , Masculino , Pessoa de Meia-Idade , Neoplasias/complicações , Neoplasias/epidemiologia , Neoplasias/prevenção & controle , Pioglitazona , Fatores de Risco , Rosiglitazona , Tiazolidinedionas/administração & dosagem , Tiazolidinedionas/efeitos adversosRESUMO
A positive exercise electrocardiogram (ECG) has been proved to predict cardiovascular events in asymptomatic normolipidemic men. To study whether it is also predictive for hypercholesterolemic men, data from 3,806 asymptomatic hypercholesterolemic men in the Lipid Research Clinics Coronary Primary Prevention Trial were analyzed. All the men had performed a submaximal treadmill exercise test at baseline, before they were assigned to the cholestyramine or placebo treatment group. Because of missing or inconclusive data, 31 men were excluded from the analyses. A test was positive if the ST segment was displaced by greater than or equal to 1 mm (visual code) or there was greater than or equal to 10 microV-s change in the ST integral (computer code), or both. The prevalence of a positive test was 8.3%. During the 7 to 10 year (mean 7.4) follow-up period, the mortality rate from coronary heart disease was 6.7% (21 of 315) in men with a positive test and 1.3% (46 of 3,460) in men with a negative test (placebo and cholestyramine groups combined). The age-adjusted rate ratio for a positive test, compared with a negative test, was 6.7 in the placebo group and 4.8 in the cholestyramine group. With use of Cox's proportional hazards models, it was found that the risk of death from coronary heart disease associated with a positive test was 5.7 times higher in the placebo group and 4.9 times higher in the cholestyramine group after adjustment for age, smoking history, systolic blood pressure, high density lipoprotein cholesterol and low density lipoprotein cholesterol. A positive test was not significantly associated with nonfatal myocardial infarction.(ABSTRACT TRUNCATED AT 250 WORDS)
Assuntos
Doença das Coronárias/mortalidade , Hipercolesterolemia/complicações , Valor Preditivo dos Testes , Doença das Coronárias/etiologia , Doença das Coronárias/fisiopatologia , Doença das Coronárias/prevenção & controle , Eletrocardiografia , Teste de Esforço , Seguimentos , Humanos , Masculino , Pessoa de Meia-Idade , Fatores de RiscoRESUMO
BACKGROUND: Previous studies often of short duration have raised concerns that antihypertensive therapy with diuretics and beta-blockers adversely alters levels of other cardiovascular disease risk factors. METHODS: The Systolic Hypertension in the Elderly Program was a community-based, multicenter, randomized, double-blind, placebo-controlled clinical trial of treatment of isolated systolic hypertension in men and women aged 60 years and older. This retrospective analysis evaluated development of diabetes mellitus in all 4736 participants in the Systolic Hypertension in the Elderly Program, including changes in serum chemistry test results in a subgroup for 3 years. Patients were randomized to receive placebo or treatment with active drugs, with the dose increased in stepwise fashion if blood pressure control goals were not attained: step 1, 12.5 mg of chlorthalidone or 25.0 mg of chlorthalidone; and step 2, the addition of 25 mg of atenolol or 50 mg of atenolol or reserpine or matching placebo. RESULTS: After 3 years, the active treatment group had a 13/4 mm Hg greater reduction in systolic and diastolic blood pressure than the placebo group (both groups, P<.001). New cases of diabetes were reported by 8.6% of the participants in the active treatment group and 7.5% of the participants in the placebo group (P=.25). Small effects of active treatment compared with placebo were observed with fasting levels of glucose (+0.20 mmol/L [+3.6 mg/dL]; P<.01), total cholesterol (+0.09 mmol/L [+3.5 mg/dL]; P<.01), high-density lipoprotein cholesterol (-0.02 mmol/L [-0.77 mg/dL]; P<.01) and creatinine (+2.8 micromol/L [+0.03 mg/dL]; P<.001). Larger effects were seen with fasting levels of triglycerides (+0.9 mmol/L [+17 mg/dL]; P<.001), uric acid (+35 micromol/L [+.06 mg/dL]; P<.001), and potassium (-0.3 mmol/L; P<.001). No evidence was found for a subgroup at higher risk of risk factor changes with active treatment. CONCLUSIONS: Antihypertensive therapy with low-dose chlorthalidone (supplemented if necessary) for isolated systolic hypertension lowers blood pressure and its cardiovascular disease complications and has relatively mild effects on other cardiovascular disease risk factor levels.
Assuntos
Anti-Hipertensivos/administração & dosagem , Glicemia/efeitos dos fármacos , Clortalidona/administração & dosagem , Diuréticos/administração & dosagem , Hipertensão/sangue , Hipertensão/tratamento farmacológico , Lipídeos/sangue , Potássio/sangue , Ácido Úrico/sangue , Idoso , Anti-Hipertensivos/farmacologia , Clortalidona/farmacologia , Diuréticos/farmacologia , Método Duplo-Cego , Feminino , Humanos , Hipertensão/diagnóstico , Masculino , Fatores de Risco , Sístole , Fatores de Tempo , Resultado do TratamentoRESUMO
We compared plasma lipid changes due to the polyunsaturated fatty acids (PUFAs) in partially hydrogenated soybean oil, corn oil, and sunflower oil fed in reduced-fat diets (22-26% of total energy). Each oil was the dominant fat in isoenergetic diets of centrally prepared foods consumed by 26 male and 35 female normolipidemic, free-living individuals. Test diets were consumed double-blind, alternating with self-selected diets for 5 wk each. The ranges of proportions of total fat were: 4.7-9.7% polyunsaturated fat, 8.9-14.2% monounsaturated fat and 5.4-7.4% saturated fat. All three diets lowered (P < 0.0001) total cholesterol (11%), LDL cholesterol (13%), and HDL cholesterol (10%), without triglyceride changes. We conclude that PUFAs at approximately 6% of total energy result in clinically relevant plasma cholesterol-lowering and that the proportion of polyunsaturated fat must be an important consideration when planning reduced-fat, reduced-saturated-fat diets.
Assuntos
Colesterol/sangue , Gorduras Insaturadas na Dieta/administração & dosagem , Óleos de Plantas/administração & dosagem , Adulto , HDL-Colesterol/sangue , LDL-Colesterol/sangue , Óleo de Milho/administração & dosagem , Método Duplo-Cego , Feminino , Helianthus , Humanos , Masculino , Pessoa de Meia-Idade , Caracteres Sexuais , Óleo de Soja/administração & dosagem , Óleo de Girassol , Triglicerídeos/sangueRESUMO
This study's purpose was to evaluate the fasting human plasma lipid and lipoprotein responses to dietary beef fat (BF) by comparison with coconut oil (CO) and safflower oil (SO), fats customarily classified as saturated and polyunsaturated. Nineteen free-living normolipidemic men aged 25.6 +/- 3.5 yr consumed centrally-prepared lunches and dinners of common foods having 35% fat calories, 60% of which was the test fat. The test fats were isocalorically substituted, and each fed for five weeks in random sequences with intervening five weeks of habitual diets. Plasma total cholesterol (TC), high-density lipoprotein cholesterol (HDL-C), and low-density lipoprotein cholesterol (LDL-C) concentrations among individuals follows the same relative rank regardless of diet. Triglycerides (TG) concentrations among individuals also maintain their relative rank regardless of diet but in a different order from that of the cholesterols. Plasma TC, HDL-C, and LDL-C responses to BF were significantly lower and TG higher than to CO. As compared to SO, BF produced equivalent levels of TG, HDL-C, and LDL-C and marginally higher TC. Thus, the customary consideration of BF as "saturated" and grouping it with CO appears unwarranted.
Assuntos
Gorduras na Dieta/farmacologia , Lipídeos/sangue , Lipoproteínas/sangue , Óleos de Plantas , Adulto , Animais , Bovinos , Colesterol/sangue , HDL-Colesterol/sangue , LDL-Colesterol/sangue , Óleo de Coco , Humanos , Masculino , Produtos da Carne , Óleo de Cártamo/farmacologia , Triglicerídeos/sangueRESUMO
The abilities of 68 professional staff members (physicians, physician assistants, dietitians, nurses, and counselors) from 12 clinics of the Coronary Primary Prevention Trial of the Lipid Research Clinics Program in 28 specific skills fundamental to interviewing and counseling for medication adherence were examined. Each staff member was provided with confidential data regarding his or her abilities, and each clinic's trial director received the group data for his or her staff's possession and use of these skills. Analyses of trial-wide data showed substantial differences among clinics in possession and use of the skills, with overall greater strength in interviewing skills, as compared with assessment and counseling skills. No professional group consistently possessed most or fewest of these skills. It is suggested that trained non-physician personnel could be used to complement physician efforts to counsel patients for medication adherence.
Assuntos
Aconselhamento , Prescrições de Medicamentos , Hiperlipoproteinemia Tipo II/tratamento farmacológico , Equipe de Assistência ao Paciente , Cooperação do Paciente , Adulto , Competência Clínica , Ensaios Clínicos como Assunto , Doença das Coronárias/prevenção & controle , Método Duplo-Cego , Humanos , Entrevista Psicológica , Masculino , Pessoa de Meia-Idade , Relações Médico-Paciente , Resolução de Problemas , Controle de QualidadeRESUMO
This is a report of a successful program to return dropout participants to active participation at a single clinic of a multicenter long-term clinical trial, the Coronary Primary Prevention Trial of the Lipid Research Clinics Program. The specific objectives were to re-engage dropouts into active participation and to have them resume study medication. Thirty-six men had been absent from the Baylor-Methodist Clinic for 10 months to over four years. The program focused on resolving the presenting problems: psychosocial, somatic, and drug adherence. It was based on six general principles with corresponding goals and employed 13 activities and procedures in a specific operational sequence for reinstitution of the Coronary Primary Prevention Trial protocol. Counseling techniques were used to improve protocol adherence. The recovery program was monitored bi-weekly by computer. The dropout group did not appear to exhibit any biases and approximated the remainder of the Baylor-Methodist cohort demographically. At six months into the recovery program, 90 percent of the dropouts had been recovered. Seventy percent of the recovered participants re-established medication-taking behavior. The mean rate of adherence to medication for all of the recovered group was 35 percent of the prescribed dose, 8 g per day. Review of the data for the cholesterol differential between the two treatment groups demonstrated a favorable effect of the reinstitution of the study medication. The program's methods are applicable to clinical practice.
Assuntos
Ensaios Clínicos como Assunto/métodos , Pacientes Desistentes do Tratamento , Adulto , Colesterol/sangue , Doença das Coronárias/prevenção & controle , Aconselhamento/métodos , Método Duplo-Cego , Humanos , Hipercolesterolemia/dietoterapia , Hipercolesterolemia/tratamento farmacológico , Masculino , Pessoa de Meia-Idade , Cooperação do Paciente , Distribuição Aleatória , Texas , Fatores de TempoRESUMO
The 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors have proven to be more effective in reducing levels of low density lipoprotein (LDL) cholesterol and to be better tolerated than other lipid-lowering compounds. Most of the trials evaluating the effects of these new agents on progression of atherosclerosis have not included individuals asymptomatic for cardiovascular disease and who have LDL cholesterol levels at or below the limits established by the National Cholesterol Education Program for initiating treatment. The Asymptomatic Carotid Artery Progression Study (ACAPS) tested the effect of the HMG-CoA reductase inhibitor, lovastatin, on early-stage carotid atherosclerosis (as detected by B-mode ultrasonography) in 919 asymptomatic men and women, 40-79 years of age, who had LDL cholesterol levels between the 60th and 90th percentiles. Participants randomized into this double-blind, placebo-controlled, factorially designed study received lovastatin (20-40 mg/day) or lovastatin-placebo and warfarin (1 mg/day), or warfarin-placebo over a 3-year period. The progression of the mean maximum intimal-medial thickness (IMT) over 12 walls of both carotid arteries represented the primary outcome. Lovastatin treatment was associated with a reduction in progression of mean maximum IMT (p < 0.001). Levels of LDL cholesterol were reduced by 28% (43.5 mg/dl [11.25 mmol/liter]) in the lovastatin group within 6 months (p < 0.0001) and remained stable throughout the follow-up period, whereas these levels remained essentially unchanged in the lovastatin-placebo group. The difference in incidence of major cardiovascular events for patients in the lovastatin-placebo group was significant: 5 versus 14, respectively (p < 0.05).(ABSTRACT TRUNCATED AT 250 WORDS)
Assuntos
Anticolesterolemiantes/uso terapêutico , Arteriosclerose/tratamento farmacológico , Doenças das Artérias Carótidas/tratamento farmacológico , Inibidores Enzimáticos/uso terapêutico , Lovastatina/uso terapêutico , Adulto , Idoso , Anticoagulantes/uso terapêutico , Arteriosclerose/sangue , Arteriosclerose/diagnóstico por imagem , Artérias Carótidas/diagnóstico por imagem , Artérias Carótidas/efeitos dos fármacos , Doenças das Artérias Carótidas/sangue , Doenças das Artérias Carótidas/diagnóstico por imagem , LDL-Colesterol/sangue , Método Duplo-Cego , Feminino , Seguimentos , Humanos , Inibidores de Hidroximetilglutaril-CoA Redutases , Masculino , Pessoa de Meia-Idade , Análise Multivariada , Análise de Regressão , Resultado do Tratamento , Ultrassonografia , Varfarina/uso terapêuticoRESUMO
Recommended doses of bile-acid binding resins have an established hypocholesterolemic effect, but data on responses to low doses, especially in women and subjects with moderate hypercholesterolemia, are sparse. A double-blind, placebo-controlled, randomized trial of 3 low doses of colestipol hydrochloride was conducted in women and men with moderate hypercholesterolemia. Men and women with plasma low-density lipoprotein (LDL) cholesterol concentrations greater than 4 mmol/liter (155 mg/dl) and triglyceride concentrations less than 2.82 mmol/liter (250 mg/dl) were recruited for the study. Eligible patients (54 women and 98 men) were placed on the American Heart Association step I diet 6 weeks before randomization. Participants were subsequently assigned to 1 of 4 drug treatment groups (placebo, and 5, 10 and 15 g/day of colestipol in 2 divided doses) for an additional 12 weeks. Of the 152 patients randomized, 141 completed all aspects of the study. For the treatment groups--placebo, and 5, 10 and 15 g of colestipol--LDL cholesterol reductions (mmol/liter) were observed respectively (n = 141): 0.10 +/- 0.49 (2.7%), 0.65 +/- 0.41 (16.3%), 0.98 +/- 0.36 (22.8%) and 1.17 +/- 0.47 (27.2%) (p less than 0.001). Similar changes were observed in total cholesterol and apolipoprotein B concentrations. The apolipoprotein B/LDL cholesterol ratio increased significantly with increasing colestipol dosage. Modest but insignificant changes in plasma triglyceride levels occurred, and high-density lipoprotein cholesterol levels remained unchanged. A dose of 5 g/day of colestipol achieved 51% of the LDL cholesterol reduction noted with 15 g/day. Low-dose colestipol therapy is effective in the treatment of patients with moderate hypercholesterolemia.(ABSTRACT TRUNCATED AT 250 WORDS)
Assuntos
Colestipol/administração & dosagem , Hipercolesterolemia/tratamento farmacológico , Adulto , Colesterol/sangue , Colestipol/efeitos adversos , Método Duplo-Cego , Avaliação de Medicamentos , Feminino , Humanos , Hipercolesterolemia/sangue , Lipoproteínas/sangue , Lipoproteínas/efeitos dos fármacos , Masculino , Pessoa de Meia-Idade , Triglicerídeos/sangue , Estados UnidosRESUMO
A decrease in high-density lipoprotein cholesterol (HDL-C), a major risk factor for coronary artery disease, occurs during puberty in males. Previous studies have shown this decrease with testosterone (T) therapy for adolescent males, but the mechanism of this effect is unknown and has not been studied in a non-human primate. Two adult male monkeys (Macaca fascicularis) were studied to determine simultaneous changes in plasma androgens and HDL-C during the phases precastration (Ci); postcastration (Cx); Cx and T therapy; Cx and dihydrotestosterone (DHT) therapy; and T and 5-alpha-reductase inhibitor therapy (4-MA). After castration, the HDL-C concentrations increased significantly in both animals (monkey A, 57.0 +/- 1.8 mg/dL SE to 66.6 +/- 2.2, P less than .005; monkey B, 62.9 +/- 1.6 to 80.2 +/- 1.7, P less than .001). T-propionate treatment produced a significant decrease in HDL-C (monkey A, 48.0 +/- 5.0, P less than .01; monkey B, 43.5 +/- 0.5, P less than .001), which was similar to HDL-C reductions seen when treated with a nonaromatizeable androgen, DHT-propionate (monkey A, 47.5 +/- 1.5, P less than .005; monkey B, 44.5 +/- 3.5, P less than .001). T and the 5-alpha-reductase inhibitor therapy did not increase HDL-C from the levels with T therapy alone (monkey A, 55.7 +/- 1.9, NS; monkey B, 57.3 +/- 0.3, NS).(ABSTRACT TRUNCATED AT 250 WORDS)
Assuntos
Arteriosclerose/prevenção & controle , HDL-Colesterol/sangue , Di-Hidrotestosterona/farmacologia , Lipoproteínas HDL/sangue , Testosterona/farmacologia , Inibidores de 5-alfa Redutase , Androstanos/farmacologia , Animais , Azasteroides/farmacologia , Di-Hidrotestosterona/sangue , Modelos Animais de Doenças , Macaca fascicularis , Masculino , Orquiectomia , Testosterona/sangueRESUMO
Serum total carotenoid (STC) and vitamin A levels were done as part of the biochemical screening in comparative studies of lipid lowering agents in type Ila hyperlipoproteinemic patients. STC levels were reduced following bile acid sequestering agent administration (colestipol 30 g/d) by 30% (P less than 0.01). Clofibrate and avicel placebo had inconsistent and nonsignificant effects on the STC levels. Serum vitamin A levels were not significantly altered by any of the test agents. The STC level changes were not correlated with concomitant changes in low-density lipoprotein-cholesterol (LDL-C) during any of the treatment regimens. It is suggested that STC level changes are related to alterations in the absorption of carotenoids during bile acid sequestrant administration.
Assuntos
Anticolesterolemiantes/uso terapêutico , Carotenoides/sangue , Hiperlipoproteinemia Tipo II/tratamento farmacológico , Vitamina A/sangue , Adulto , Análise de Variância , Celulose/farmacologia , LDL-Colesterol/sangue , Clofibrato/farmacologia , Colestipol/farmacologia , Humanos , Hiperlipoproteinemia Tipo II/sangue , Pessoa de Meia-IdadeRESUMO
Total serum alkaline phosphatase (TSAP) determinations were done as part of the biochemical screening in comparative studies of lipid lowering agents in type lla hyperlipoproteinemic patients. TSAP determinations were made by using a modification of the Bessey-Lowry method and the Statland method. Increases in TSAP following colestipol treatment of 20% (P less than 0.05) and 32% (P less than 0.005) were seen by using the respective methods. Isoenzymatic determinations were done by employing the Statland method and all fractions were increased from baseline levels during colestipol therapy. Clofibrate was associated with 34% (P less than 0.005) and 28% (P less than 0.005) reductions in TSAP activity by using the respective methods; significant reductions in both "bone" and "other" isoenzymatic components occurred. Gamma-glutamyltransferase (gamma GT) results did not consistently reflect TSAP or "liver" isoenzyme results.
Assuntos
Fosfatase Alcalina/sangue , Clofibrato/farmacologia , Colestipol/farmacologia , Isoenzimas/sangue , Poliaminas/farmacologia , Adulto , Humanos , Pessoa de Meia-Idade , gama-Glutamiltransferase/sangueRESUMO
The effects of 2.0 g of clofibrate and 15, 20 and 30 g of colestipol on plasma lipid and lipoprotein levels were evaluated in adult patients with Type IIa hyperlipoproteinemia. Clofibrate treatment was associated with decreases in 11.0% in plasma cholesterol. 15.2% in LDL cholesterol, 26.1% in triglycerides, and an 11.3% increase in HDL cholesterol. The reductions in total cholesterol with the various doses of colestipol ranged from 11.9 to 17.8% and reductions in LDL cholesterol ranged from 16.1 to 27.3%. Colestipol treatment was not associated with any significant change in HDL cholesterol levels and minor increases in triglycerides. The addition of clofibrate to patients receiving colestipol resulted in a significant increase in HDL cholesterol and a decrease in triglycerides, but no additional reduction in total or LDL cholesterol.
Assuntos
Clofibrato/uso terapêutico , Colestipol/uso terapêutico , Hiperlipoproteinemia Tipo II/tratamento farmacológico , Lipídeos/sangue , Lipoproteínas/sangue , Poliaminas/uso terapêutico , Adulto , Colesterol/sangue , HDL-Colesterol , LDL-Colesterol , Relação Dose-Resposta a Droga , Humanos , Hiperlipoproteinemia Tipo II/sangue , Lipoproteínas HDL/sangue , Lipoproteínas LDL/sangue , Pessoa de Meia-Idade , Triglicerídeos/sangueRESUMO
In an attempt to determine the minimum dose of D-Thyroxine (D-T4) which will suppress pituitary TSH response to TRH, we have treated 6 euthyroid, hypercholesterolemic patients with graded doses of D-T4. TSH response was suppressed in 3 patients with 3 mg and in the remaining 3 patients with 4 mg D-T4 administered once daily. The mean TSH suppressive dose of 3.5 mg, as determined in this study, is considerably less than the 6 mg daily dose given to patients treated with D-T4 in the Coronary Drug Project. This suggests that the adverse effects observed with D-T4 treatment in the Coronary Drug Project may have been due to mild, undetected hyperthryroidism. D-T4 treatment in our patients was not associated with an increase in heart rate or ventricular ectopic beats as determined by Holter monitoring. However, bile samples obtained at the time of TSH suppression showed a significant increase in lithogenic index. In four patients, TSH suppressive doses of D-T4 were associated with a 12% decrease in mean cholesterol and a 17% decrease in mean LDL cholesterol concentrations.
Assuntos
Dextrotireoxina/uso terapêutico , Hiperlipoproteinemia Tipo II/tratamento farmacológico , Hormônio Liberador de Tireotropina , Tireotropina/sangue , Adulto , Bile/efeitos dos fármacos , Bile/metabolismo , Colesterol/metabolismo , Dextrotireoxina/administração & dosagem , Relação Dose-Resposta a Droga , Avaliação de Medicamentos , Feminino , Humanos , Hiperlipoproteinemia Tipo II/sangue , Masculino , Pessoa de Meia-IdadeRESUMO
Adherence in clinical trials is a consistent problem regardless of the disease process or organ system under investigation. In this paper data and examples from clinical trials examining cardiovascular diseases are used as the basis for a review of various adherence principles. Issues reviewed include: the importance of adherence in clinical trials, an overall program for adherence in clinical trials, and specific issues in adherence from arthritis clinical trials. Special attention is given to a program for the prevention of reduced adherence for participants of a clinical trial as well as acute and chronic intervention plans for those with good adherence and those with reduced adherence in a clinical trial.
Assuntos
Artrite/psicologia , Ensaios Clínicos como Assunto , Cooperação do Paciente , Artrite/terapia , Terapia Comportamental , Aconselhamento , HumanosRESUMO
Dietitians who want to expand their clinical responsibilities beyond dietary counseling should consider the role of the intervention specialist. The role is a logical expansion of the duties of the dietitian who is already serving as a health behavior counselor. The concept of dietitians' functioning as intervention specialists originated in clinical trials, when they served as adherence counselors. The intervention specialists in the clinical trials used the health behavior counseling process to help research participants adhere to the trials' protocols. This counseling process uses a systematic, problem-solving approach to assess, diagnose, intervene, and follow up on a targeted behavioral problem. Dietitians can prepare for the expanded counseling role of intervention specialist through interviewing and counseling skill assessment and further training. They must take an active role in defining how the services of an intervention specialist can be beneficial to physicians as well as to their patients. They should address the cost-effectiveness of behavior counseling in order to justify the increased initial costs. Dietitians will need to actively promote the role of intervention specialist in the medical community if they want this opportunity for increased professional responsibility.
Assuntos
Aconselhamento , Dietética , Terapia Comportamental , Promoção da Saúde , Humanos , Resolução de ProblemasRESUMO
The Systolic Hypertension in the Elderly Program (SHEP) encompasses two clinical trials--a pilot study and a full-scale trial--investigating the safety and efficacy of antihypertensive therapy for patients aged 60 years and over with isolated systolic hypertension (ISH), that is, systolic blood pressure (SBP) greater than or equal to 160 mmHg and diastolic blood pressure (DBP) less than 90 mmHg. An optimal result of the full-scale trial should lead to recommendations for prescription of effective therapy that preserves the quality of life while reducing the long-term risks of stroke, other cardiovascular disease, and death. This article briefly describes the design, protocol, and organization for the pilot and fullscale SHEP studies. In these trials the nurses help plan study protocol, coordinate patient recruitment, provide patient care, and maintain protocol compliance. In order to accomplish their role in data collection and reporting, they undergo comprehensive training and certification. Nurses utilize the multicenter clinical trial as an opportunity to participate in research, both independently and collaboratively. The specific roles of nurses within these trials, as well as features of these trials that relate to nursing practice and research, are discussed.